BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharma is well-positioned for long-term success with its diverse pipeline targeting various therapeutic areas, strong revenue growth projections, and cost-cutting measures leading to improved profitability. With a strong focus on rare diseases and a track record of successful deals, the company is likely to continue prioritizing acquisitions and partnerships in niche areas, while also pursuing external innovation opportunities. However, there is a potential clinical risk in the failure of its Netherton Syndrome program and the efficacy of its kallikrein inhibitors. Financially, BioCryst reported higher than expected total revenue in 2Q26 and lowered its non-GAAP operating expense guidance, demonstrating strong financial management.

BioCryst Pharma is currently facing challenges with their Orladeyo pellet formulation and their transition to a new specialty pharmacy in 3Q26. This is causing a slowdown in revenue growth in FY26, but the potential for growth in the long-run as they expand into the pediatric market. Their recent financial results beat consensus estimates, but there is still a risk of failure to execute commercially or competition from other players in the HAE market. Additionally, their R&D strategy and cost structure have been refined, which has led to a higher price target of $29 but with reduced revenue expectations for their navenibart program. Overall, BioCryst Pharma's near-term challenges and long-term potential result in a negative outlook.